Aderbasib is an orally available small molecule inhibitor targeting ADAM metalloproteases. It is being investigated as a potential pharmaceutical compound for cancer research, particularly in the context of breast cancer.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 791828-58-5
Cyclosporine
pharmaceutical raw material
Acrylfentanyl hydrochloride
pharmaceutical raw material
Azelastine hydrochloride
pharmaceutical raw material
(6R-trans)-7-[[(2-Amino-4-thiazolyl)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid
pharmaceutical raw material
methyl (6S,7S)-7-(hydroxycarbamoyl)-6-(4-phenylpiperazine-1-carbonyl)-5-azaspiro[2.5]octane-5-carboxylate
DJXMSZSZEIKLQZ-IRXDYDNUSA-N
COC(=O)N1CC2(CC2)C[C@@H]([C@H]1C(=O)N3CCN(CC3)C4=CC=CC=C4)C(=O)NO